contextflow & Curagita partner to improve lung cancer and lung disease diagnostics in Germany
Curagita AG, a market-leading healthcare services company specializing in innovative management solutions for radiology practices and hospitals – including on-premises platforms for clinical, technical, and administrative AI applications, and contextflow, the Vienna-based radiology AI chest experts, announce a commercial partnership to enable radiologists access to contextflow ADVANCE Chest CT in support of improved lung cancer and lung disease diagnostics.
Under the partnership, contextflow’s innovative computer-aided detection support for chest CT will be integrated into the Curagita’s CuraHub on-premises marketplace. CuraHub enables imaging centers to deploy and test various AI algorithms quickly, easily and reliably, allowing these centers to focus on their core business rather than IT-related issues.
contextflow’s core technology is ADVANCE Chest CT, an AI-based medical device software. It detects, visualizes and quantifies nodules and lung disease patterns to improve the speed and quality of radiology reporting with consistent, objective information. ADVANCE Chest CT’s malignancy scoring feature has been shown to not only detect lung cancer sooner but also to reduce both false positives and false negatives (*Adams, Scott J et al., JACR September 2022).
In regards to the partnership’s history, contextflow Chief Commercial Officer Marcel Wassink explains, “Curagita offers clinicians a comprehensive AI-based clinical workflow management tool, and contextflow offers radiologists comprehensive AI-based detection software for lung cancer and lung diseases. The synergies are quite clear, and it has been a long-held goal of ours to combine these two technologies into one offering to streamline daily radiological processes related to chest CT.”
In addition to increased access to clinical decision support for chest CT, the partnership aims to reduce false positives and patient stress in relation to lung cancer detection via malignancy scoring. Malignancy scoring enables a radiologist to compare suspicious nodules to thousands of others with known outcomes in order to indicate the probability that a given nodule is malignant or benign. Malignancy scoring has been validated in a clinical study to reduce false positive nodule detection by 18% while detecting lung cancer up to one year earlier.
As Daniel Reiberg at Curagita AG explains, “contextflow, with its wide range of features and intuitive user interface, helps our customers to improve lung diagnostics. In addition, it helps radiologists strengthen the referral relationship by providing important information such as nodule growth and volume in a quickly perceptible way.”
Contact
Julie Sufana, Chief Marketing Officer, contextflow, email: julie@contextflow.com
Curagita AG
Eva Jugel, Procurist, Curagita AG, email: eju@curagita.com